Ipamorelin and the engineering ideal of a clean signal.

Cyril Bowers at Tulane University synthesized GHRP-6 in the 1980s and discovered, by accident, a class of peptides that released growth hormone through a receptor that nobody yet knew existed. The receptor — GHSR-1a, the ghrelin receptor — was identified in 1996 by Howard and colleagues at Merck. The endogenous ligand, ghrelin, was identified in 1999 by Kojima and Kangawa in Tokyo. The peptide field, in other words, found the drug class first and the biology second. By the time ghrelin was isolated, several synthetic GH secretagogues were already in clinical development, including a problematic feature that the medicinal-chemistry teams could not initially solve: the molecules released growth hormone, but they also released cortisol, prolactin, ACTH, and aldosterone. The signal was dirty.

The 1998 paper

Kirsten Raun and her colleagues at Novo Nordisk in Denmark published the answer in the European Journal of Endocrinology in November 1998. The paper introduced ipamorelin, a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was structurally derived from GHRP-1 but with a key conformational rigidification — the alpha-aminoisobutyric acid at position 1 enforces a beta-turn that the team's modeling work suggested was the bioactive conformation at GHSR-1a. The result, in their published data: ipamorelin released GH with an EC50 in the low-nanomolar range, and at doses more than 200-fold higher than the GH ED50, it produced no statistically significant elevations in ACTH, cortisol, prolactin, FSH, LH, or TSH.

Selectivity, in this case, was not a regulatory talking point. It was a chemical achievement that took the field fifteen years to accomplish.

The molecule's other notable property is its short half-life — roughly two hours in human plasma. The combination of a clean release signal, brief duration, and absent cross-reactivity made ipamorelin the cleanest tool the GH-axis literature had for asking mechanistic questions.

The clinical detour: postoperative ileus

GHSR-1a is expressed in the gastric fundus and along the enteric nervous system. The pharmaceutical inference was that ipamorelin, as a GHSR-1a agonist, might shorten postoperative ileus. Helsinn Therapeutics ran a phase 2b trial published in the International Journal of Colorectal Disease in 2014, randomizing 117 bowel-resection patients to twice-daily intravenous ipamorelin or placebo for up to seven days. The drug was well tolerated. It missed the primary endpoint.

The non-obvious findings

First: bone. A 2000 paper by Svensson, Lall, and colleagues in the Journal of Bone and Mineral Research — work conducted at AstraZeneca's research division in Mölndal, Sweden — showed that adult female rats given ipamorelin for fifteen weeks gained measurable bone mineral content. The effect was demonstrable at trabecular sites and resisted the usual age-related decline. The mechanism appears to combine GH/IGF-1-mediated osteoblast stimulation with possible direct GHSR-1a effects on bone-marrow stromal cells, where Delhanty and colleagues at Erasmus University Rotterdam later demonstrated GHSR-1a expression and ghrelin-induced osteoblast mitogenesis.

Second: the absence of off-target signaling is itself the finding. Most GH secretagogues raise cortisol enough to confound any chronic-dosing protocol; ipamorelin's failure to do so is what makes it the reference compound for isolating GHSR-1a effects from HPA-axis effects.

Why the half-life shapes the research protocol

Two hours is short. CJC-1295 DAC's six-to-eight-day half-life is long. The combination produces a research-protocol logic that is sometimes read as ad-hoc but is in fact mechanistic. Ipamorelin acts on GHSR-1a to amplify the amplitude and frequency of GH pulses. CJC-1295 acts on the GHRHR to raise the baseline tone against which those pulses occur. The somatotroph integrates the two signals.

Often studied alongside

The canonical pairing in the research literature is ipamorelin with CJC-1295, for the receptor-pathway reasons described above. Tesamorelin appears in the same neighborhood as a long-acting GHRHR agonist with FDA-approved status; tesamorelin and ipamorelin are not typically studied together because they would functionally overlap with the CJC-1295/ipamorelin combination already characterized.

The 2024 anamorelin work in osteosarcopenia by Garcia and colleagues in JCEM points toward a renewed interest in GHSR-1a agonists for clinical bone and muscle indications, where ipamorelin's selectivity profile would, in principle, be an advantage if a sponsor were to pursue formal development.